Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KLRK1 | P26718 | 5/20 | 0.42 |
| ▸ | MICA | Q29983 | 5/20 | 0.42 |
| ▸ | RAET1L | Q5VY80 | 4/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | MTTP | P55157 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449921 | 1.00 | TNFRSF1A (0.46) | TNFRSF1ATACR3ALDH1A1RXFP1KLRK1 | |
| SCHEMBL4450981 | 0.86 | TNFRSF1A (0.45) | TNFRSF1AALDH1A1RXFP1LMNA | |
| SCHEMBL4450978 | 0.86 | TNFRSF1A (0.45) | TNFRSF1AALDH1A1RXFP1LMNA | |
| SCHEMBL4451029 | 0.86 | TNFRSF1A (0.48) | TNFRSF1ATACR3ALDH1A1RXFP1S1PR3 | |
| SCHEMBL4457047 | 0.86 | TNFRSF1A (0.48) | TNFRSF1ATACR3ALDH1A1RXFP1S1PR3 | |
| SCHEMBL4451030 | 0.86 | TNFRSF1A (0.48) | TNFRSF1ATACR3ALDH1A1RXFP1S1PR3 | |
| SCHEMBL4447516 | 0.85 | TNFRSF1A (0.47) | TNFRSF1ATACR3ALDH1A1RXFP1S1PR3 | |
| SCHEMBL4450275 | 0.85 | TNFRSF1A (0.47) | TNFRSF1ATACR3ALDH1A1RXFP1S1PR3 | |
| SCHEMBL4447518 | 0.85 | TNFRSF1A (0.47) | TNFRSF1ATACR3ALDH1A1RXFP1S1PR3 | |
| SCHEMBL4446583 | 0.77 | TNFRSF1A (0.46) | TNFRSF1AALDH1A1RXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | TNFRSF1A 3963/4885TACR3 556/4885ALDH1A1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.